Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Concurrent chemotherapy and KN026|DRUG: KN026 monotherapy|DRUG: KN026 combination
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd